NCT01821911 is a Phase 4 clinical trial of Zagreb2-1-1 in Rabies Vaccine Allergy, sponsored by Beijing Center for Disease Control and Prevention.

Who is sponsoring NCT01821911?

NCT01821911 is sponsored by Beijing Center for Disease Control and Prevention.

What drugs are being tested in NCT01821911?

Interventions in NCT01821911: Zagreb2-1-1, Essen.

What condition does NCT01821911 study?

NCT01821911 studies Rabies Vaccine Allergy, Vaccination Adverse Event, Anti-D Antibodies.

Is NCT01821911 still recruiting?

NCT01821911 is currently completed. Last updated 19 January 2016.

Last reviewed 2016-01-19 · How we verify

NCT01821911

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 4 Study of Speeda® Rabies Vaccine for Human Use

Completed Phase 4 Last updated 19 January 2016

What this trial tests

Phase 4 trial testing Zagreb2-1-1 in Rabies Vaccine Allergy in 10,500 participants. Completed in 1 December 2014.

Timeline

1 July 2012

Primary endpoint
1 December 2013

1 December 2014

Quick facts

Lead sponsor	Beijing Center for Disease Control and Prevention
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	10,500
Start date	1 July 2012
Primary completion	1 December 2013
Estimated completion	1 December 2014
Sites	3 locations across China

Drugs / interventions tested

Zagreb2-1-1 — full drug profile →
Essen — full drug profile →

Conditions studied

Rabies Vaccine Allergy — all drugs for Rabies Vaccine Allergy →
Vaccination Adverse Event — all drugs for Vaccination Adverse Event →
Anti-D Antibodies — all drugs for Anti-D Antibodies →

Sponsor

Beijing Center for Disease Control and Prevention — full company profile →

Who can join

Eligibility, any sex, with Rabies Vaccine Allergy or Vaccination Adverse Event. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Incidence Rate of Adverse Events of the rabies vaccine each injection
Time frame: 2 years

Sponsor's own description

The objective of this study was to achieve the post-marketing safety and immunogenicity research of Speeda® rabies vaccine for human use from Chengda Bio

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects.
Shi N, Zhang Y, Zheng H, Zhu Z, et al · · 2017 · cited 19× · PMID 28121231 · DOI 10.1080/21645515.2017.1279770

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01821911 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Center for Disease Control and Prevention
Last refreshed: 19 January 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01821911.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing